HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes

Journal of Molecular Medicine

Volumn 81, Issue 1, 2003, Pages 43-50

  Gjertsen, Marianne Klemp ^b   Sæterdal, Ingvil ^b   Sæebøe Larssen, Stein ^b   Gaudernack, Gustav ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cytotoxic T lymphocytes; Granulocyte macrophage colony stimulating factor; p21 ras; Pancreatic cancer; Peptide vaccination

Indexed keywords

EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA A3 ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; LYSYLLEUCYLVALYLVALYLVALYLGLYCYLALANYLARGINYLGLYCYLVALYLGLYCYLLYSYLSERYLALA NYLLEUCYLTHREONYLISOLEUCINE; LYSYLLEUCYLVALYLVALYLVALYLGLYCYLALANYLASPARTYLGLYCYLVALYLGLYCYLLYSYLSERYLAL ANYLLEUCYLTHREONYLISOLEUCINE; LYSYLLEUCYLVALYLVALYLVALYLGLYCYLALANYLCYSTEINYLGLYCYLVALYLGLYCYLLYSYLSERYLA LANYLLEUCYLTHREONYLISOLEUCINE; LYSYLLEUCYLVALYLVALYLVALYLGLYCYLALANYLGLYCYLGLYCYLVALYLGLYCYLLYSYLSERYLALAN YLLEUCYLTHREONYLISOLEUCINE; LYSYLLEUCYLVALYLVALYLVALYLGLYCYLALANYLVALYLGLYCYLVALYLGLYCYLLYSYLSERYLALANY LLEUCYLTHREONYLISOLEUCINE; RAS PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOTHERAPY; IN VIVO STUDY; LYMPHOCYTE CLONE; MONONUCLEAR CELL; MUTATION; PANCREAS ADENOCARCINOMA; VACCINATION;

EID: 0037280283     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-002-0390-y     Document Type: Article

References (38)

1. Van der Bruggen P, Traversari C, Chomez P Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643
2. Brichard V, van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489
3. Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA (1998) Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 161:6985
4. Bourgault Villada I, Beneton N, Bony C, Connan F, Monsonego JA, Saiag P, Levy JP, Guillet JG, Choppin J (2000) Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18 motif. Eur J Immunol 30:2281
5. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Sette A, Celis E (1998) The multi-epitope approach for immunotherapy for cancer identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1
6. Brodsky FM, Lem L, Bresnahan PA (1996) Antigen processing and presentation. Tissue Antigens 47:464
7. Townsend A, Bodmer H (1989) Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601
8. Eisenlohr LC, Yewdell JW, Bennink JR (1992) A transient transfection system for identifying biosynthesized proteins processed and presented to class I MHC restricted T lymphocytes. J Immunol Methods 154:131
9. Rock KL, Rothstein L, Benacerraf B (1992) Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc Natl Acad Sci USA 89:8918
10. Rudensky AY, Preston-Hulburt P, Hong SC, Barlow A, Janeway Jr CA (1991) Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622
11. Romagnani S (1999) Th1/Th2 cells. Inflamm Bowel Dis 5:285
12. Steinmann RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271
13. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682
14. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-k-ras genes. Cell 53:549
15. Appleman LJ, Frey AB (1996) Tumor antigens encoded by oncogenes and the impact of oncogenes upon the immune response. Cell Immunol 170:1
16. Jung S, Schluesener HJ (1991) Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 73:273
17. Gedde-Dahl III T, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G (1992) Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln→Leu61). Int Immunol 4:1331
18. Fossum B, Gedde-Dahl III T, Breivik J, Eriksen JA, Spurkland A, Thorsby E, Gaudernack G (1994) p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int J Cancer 56:40
19. Tsang KY, Nieroda CA, DeFilippi R, Chung YK, Yamaue H, Greiner JW, Schlom J (1994) Induction of human cytotoxic T cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res 3:183
20. Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, Bertram KA, Fenton RG, Peace DJ, Cheever MA (1995) CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 55:2984
21. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJM, Schrier PI (1995) Induction and characterization of cytotoxic T lymphocytes recognizing a mutated p21 ras peptide presented by HLA-A*0201. Int J Cancer 61:389
22. Gjertsen MK, Bakka A, Breivik J, Sæterdal I, Gedde-Dahl III T, Stokke KT, Solheim BJ, Egge TS, Søreide O, Thorsby E, Gaudernack G (1995) Vaccination with mutant ras peptides and induction of T cell responsiveness in pancreatic-carcinoma patients after mutant ras peptide vaccination. Lancet 346:1399
23. Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J (1999) A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 22:155
24. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, Eriksen JA, Møller M, Baksaas I, Lothe RA, Aæterdal I, Gaudernack G (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441
25. Gjertsen MK, Bjørheim J, Saeterdal I, Myklebust J, Gaudernack G (1997) Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12-Val dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 72:784
26. Abrams SI, Kleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J (1997) Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 182:137
27. Rammensee H, Friede T, Stefanovic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178
28. Norheim-Andersen S, Breivik J, Løvig T, Meling GI, Gaudernack G, Clausen OPF, Schjølberg A, Fausa O, Langmark F, Lund E, Rognum TO (1996) K-RAS mutations and HLA-DR expression in large bowel adenomas. Br J Cancer 74:99
29. Sæbøe-Larssen S, Fossberg E, Gaudernack G (2001) mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 8956
30. Bertazzoli C, Marchesi E, Dermime S, Ravagnani F, Parmiani G, Gambacorti-Passerini C (1997) HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins. Tumori 83:847
31. Sidney J, Grey HM, Kubo RT, Sette A (1996) Practical, biochemical and evolutionary implications for the discovery of HLA class I supermotifs. Immunol Today 17:261
32. Maeurer MJ, Gollin SM, Martin D, Swancy W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT (1996) Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/melan-A antigen. J Clin Investig 98:1633
33. Seliger B, Maeurer MJ, Ferrone S (1997) TAP off - tumors on. Immunol Today 18:292
34. Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753
35. Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu YX, Rowley DA, Schreiber H (2000) Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 191:1945
36. Nestle FO, Alijagic S, Gilliet M, Sun Y, Crabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328
37. Rosenberg SA, Yang JC, Schwarzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
38. Whiteside TL (2000) Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin Diagn Lab Immunol 7:327